Both chlorofluorocarbon (CFC)- and hydrofluoroalkane (HFA)-containing albuterol metered-dose inhalers have been in short supply, according to an FDA announcement. While some manufacturers have had temporary supply shortages, other companies have maintained normal production.
A recent Supreme Court decision bolsters the argument for state regulation of drug compounding, according to the International Academy of Compounding Pharmacists. The decision reaffirmed state jurisdiction in regulating the medical profession by rejecting DEA's position that federal law prohibits prescribing drugs under Oregon's physician-assisted suicide law.
RelayHealth has agreed to offer its consumer clients the ability to route new scripts and refill authorizations through the SureScripts Electronic Prescribing Network and to use the medication history services of community pharmacies. RelayHealth contends its eScript solution is the only on-line Rx and renewal service that includes consumers in the e-prescribing process.
The parents of a California teenaged debate champion who committed suicide seven weeks after getting fluoxetine on-line have sued the Web site, the prescribing doctor, and the pharmacy for negligence and wrongful death. The parents of John McKay allege that the 19-year-old ordered the anti-depressant from USAnet.com that a Colorado psychiatrist whose prescriptive authority was revoked wrote the Rx without examining him, and that a Mississippi-based community pharmacy dispensed the drug.
CVS has reported that the U.S. Securities & Exchange Commission has started an informal inquiry into how it accounted for a barter transaction in 2000 that involved stuffed animals. The company's audit committee has determined that accounting for the 2000 transaction was incorrect, CVS said in a filing with the SEC.
Pharmacists are urged to complete an on-line poll about Medicare Part D being conducted by the National Council of State Pharmacy Association Executives and state pharmacy associations. The survey is being conducted to gauge the experience and concerns of pharmacists about Part D since its implementation.
People with lower-extremity peripheral arterial disease (PAD) should get treatment, including pharmaceutical treatment, comparable to that for people with established coronary artery disease. That's according to new, comprehensive guidelines on PAD from the American Heart Association (AHA) and other medical groups.
A 58-year-old man, G.C., is hospitalized with an acute myocardialinfarction (MI). His physician has prescribed metoprolol, ramipril,warfarin, and atorvastatin (Lipitor, Pfizer), but is debatingwhether to continue G.C.'s bedtime chlorpromazine 400 mg, whichhe's taken for 20 years for schizophrenia, or switch to a newermedication. G.C. is showing signs of tardive dyskinesia (TD). Hisrecent records show normal fasting blood glucose levels. His BMI is22. He is a smoker. His physician asks your opinion aboutantipsychotic therapy. What do you recommend?
Small signs of resistance to imatinib (Gleevec, Novartis) emerged soon after the drug's approval in 2001 as the first oral tyrosine kinase inhibitor for chronic myeloid leukemia (CML). But second-generation drugs with similar mechanisms of action were already in the pipeline, according to studies presented at the recent 2005 ASH annual meeting, held in Atlanta. Generally about 20% of CML chronic-phase patients relapse after three years of imatinib therapy, researchers pointed out.
New software and hardware
Pharmacists can and should prove that their treatments provide a significant return on investment (ROI), said Fred Pane, R.Ph., senior director of pharmacy affairs at Premier Inc., the San Diego group purchasing organization. "Pharmacists can move from a compartmentalized budget and expense analysis model to an overall cost-of-care model," he said. "The data exist to establish that the work they do generates the best patient outcomes, with a positive effect on overall costs and reimbursements."
Not only do 11% of serious medication errors involve insulin misadministration, but the same errors seen today have been documented at least as far back as 1975. These were but two of the points Matthew Grissinger, R.Ph., used to emphasize the importance of health-system insulin safety during February's ISMP teleconference, "Preventing Errors with Insulin: A Multidisciplinary Approach."
Oncology care faces two cliffs, said Lee Schwartzberg, M.D., board member of the Community Oncology Alliance (COA): a planned $400 million to $500 million in Medicare cuts and severe payment cuts announced by private insurers. An access-to-treatment crisis was averted primarily by the addition of $400 million in funding through the implementation of a Centers for Medicare & Medicaid Services oncology demonstration project at the end of 2004. Schwartzberg, also a medical oncologist in private practice at The West Clinic in Memphis, addressed a plenary session on the Medicare Modernization Act (MMA) at the First Annual Oncology World Congress, held recently in New York City.
Reducing excessive or inappropriate antibiotic use is the best way to slow down the spread of antimicrobial resistance in bacterial infections. A report examining dozens of studies of quality-improvement (QI) interventions found that actively engaging the clinician in workshops or educational outreach on antibiotic treatment appears to be more effective than simply posting signs about correct/incorrect antibiotic use. However, most QI interventions are generally effective at reducing both inappropriate antibiotic selection and treatment.
Dissatisfied with the attention hospitals have been giving to medication reconciliation, the Joint Commission on Accreditation of Healthcare Organizations has issued a sentinel event alert, signaling the high priority it's placing on this issue.
Over the past few years, more than 2,200 U.S. soldiers have died in the wars in Iraq and Afghanistan. In addition, more than 16,000 soldiers and Marines have been wounded but have survived. Ironically, this is due largely to new, high-tech ceramic body armor and new field medical and evacuation systems.
The Food & Drug Administration has been counting on radio frequency identification (RFID) technology to be ready for widespread adoption next year, allowing drug product packages to be tagged with tiny chips containing an electronic product code or unique electronic serial number. Now the agency thinks that may not happen and is in a bit of a quandary.
Believe it or not, one in four hospitalized patients has diabetes and the annual cost of treating inpatient diabetes in the United States has reached $40 billion. These stunning statistics represent only two of the reasons why the American Association of Clinical Endocrinologists (AACE) and the American Diabetes Association (ADA) joined forces in late January to develop a position statement outlining strategies for improving inpatient glycemic control.
Not long ago, facing up to the reality that more than 50 million Americans live with persistent pain, Congress declared the period from 2001 through 2010 "The Decade of Pain Control and Research."
The number of electronic queries about Medicare Part D beneficiary eligibility has dropped since the 6.5 million peak during the first week of implementation. But pharmacists were reminded of how the system works in a recent conference call set up by the Centers for Medicare & Medicaid Services.
Why would a company that specializes in sales and marketing to the grocery, food service, drugstore, and convenience store business and an association of regional drugstore chains form a strategic alliance? If you are Federated Group and the Chain Drug Marketing Association (CDMA) the answer is to reap the benefits of sharing private-label brands.
Patients filling scripts at Bashas' United Drug pharmacies in Arizona will, like the canary in the coal mine, be the first to signal if there are problems with newly marketed drugs in the nation's first-of-its-kind active drug surveillance system.
Given the technical difficulties that led to lack of accurate beneficiary information during implementation of the Medicare Part D benefit, drug plans should let pharmacies submit claims that are up to 90 days old, according to the Centers for Medicare & Medicaid Services.
It's time to reevaluate hormone replacement therapy (HRT) in menopausal women, according to Lawrence Phillips, M.D., a professor of medicine at the Emory University School of Medicine, Atlanta.
A new vaccine that could eliminate the human papillomavirus (HPV) may soon hit the market. Because of HPV's link to cervical cancer, researchers hope the vaccine will become a standard of preventive care for adolescents.
More than 60 million adults are obese in America, putting them at risk for multiple chronic conditions like heart disease, Type 2 diabetes, respiratory problems, and possibly breast and colorectal cancer. To date, weight-loss medications have been marginally successful, due to lack of insurance coverage for an "obesity indication" and to side effects that cause patients to discontinue the drug. Enter rimonabant (Acomplia) from Sanofi-Aventis, a novel investigational agent that could be FDA-approved within months.
Authorized generics. Patent reform. Biodefense legislation. Funding for the Office of Generic Drugs (OGD). These are some of the challenges, opportunities, and issues that the Generic Pharmaceutical Association will continue to tackle in 2006 in order to lead America into a healthy future. This message was delivered by Kathleen Jaeger, GPhA president/CEO, to attendees of the association's annual meeting held recently in Boca Raton, Fla.
Many enrolled in two Part D plans
BioScrip has acquired Intravenous Therapy Services, a specialty infusion company located in Burbank, Calif. BioScrip, Elmsford, N.Y., provides pharmaceutical care solutions. The company is focused on two core areas: specialty medication distribution and clinical management services, and pharmacy benefit management services.